WCLC 2025: Study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC
A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small…
